Antiviral therapy and resistance with hepatitis B virus infection.
about
Anti-infective properties of epigallocatechin-3-gallate (EGCG), a component of green teaHepatitis B virus genotypes and lamivudine resistance mutations in JordanDistinct families of cis-acting RNA replication elements epsilon from hepatitis B virusesImpact of viral replication inhibition by entecavir on peripheral T lymphocyte subpopulations in chronic hepatitis B patients.Llama-derived single-domain intrabodies inhibit secretion of hepatitis B virions in mice.Application of hepatitis B virus replication mouse modelUnsuccessful therapy with adefovir and entecavir-tenofovir in a patient with chronic hepatitis B infection with previous resistance to lamivudine: a fourteen-year evolution of hepatitis B virus mutationsHigh expression of hepatitis B virus based vector with reporter gene in hepatitis B virus infection system.Identification of an effective siRNA target site and functional regulatory elements, within the hepatitis B virus posttranscriptional regulatory element.Viral blips during long-term treatment with standard or double dose lamivudine in HBe antigen negative chronic hepatitis BDiscovery of naturally occurring transmissible chronic hepatitis B virus infection among Macaca fascicularis from Mauritius Island.Impact of the rtI187V polymerase substitution of hepatitis B virus on viral replication and antiviral drug susceptibilityPotent inhibition of late stages of hepadnavirus replication by a modified cell penetrating peptideInhibitory effects of crude extracts from some edible Thai plants against replication of hepatitis B virus and human liver cancer cells.Epigallocatechin gallate inhibits HBV DNA synthesis in a viral replication - inducible cell line.Entecavir therapy in Turkish adult patients with chronic hepatitis B: one-year results from Izmir province, TurkeySerum levels of preS antigen (HBpreSAg) in chronic hepatitis B virus infected patients.Hepatitis B Virus Capsids Have Diverse Structural Responses to Small-Molecule Ligands Bound to the Heteroaryldihydropyrimidine PocketRISCy business: MicroRNAs, pathogenesis, and viruses.Inhibition of hepatitis B virus (HBV) gene expression and replication by HBx gene silencing in a hydrodynamic injection mouse model with a new clone of HBV genotype B.Management of hepatitis B virus co-infection on and off antiretroviral therapy.Clinical significance of 4 patients with chronic hepatitis B achieving HBsAg clearance by treated with pegylated interferon alpha-2a for less than 1 year: a short reportHepatitis B and liver transplantation: 2008 update.Quasispecies structure, cornerstone of hepatitis B virus infection: mass sequencing approach.The first transmembrane domain of the hepatitis B virus large envelope protein is crucial for infectivityDrug delivery systems and liver targeting for the improved pharmacotherapy of the hepatitis B virus (HBV) infection.Suppression of interferon-mediated antiviral immunity by hepatitis B virus: an overview of research progress.Requirement of the cyclic adenosine monophosphate response element-binding protein for hepatitis B virus replication.Genetically altering the thermodynamics and kinetics of hepatitis B virus capsid assembly has profound effects on virus replication in cell culture.Inhibition of protein kinase C phosphorylation of hepatitis B virus capsids inhibits virion formation and causes intracellular capsid accumulation.Role of glycosaminoglycans for binding and infection of hepatitis B virus.HBV RNA pre-genome encodes specific motifs that mediate interactions with the viral core protein that promote nucleocapsid assembly.Harnessing the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated Cas9 system to disrupt the hepatitis B virus.The interface between hepatitis B virus capsid proteins affects self-assembly, pregenomic RNA packaging, and reverse transcription.Detection of Hepatitis B Virus Large Surface Protein Using a Time-Resolved Immunofluorometric Assay.Validation of the INNO-LiPA HBV DR assay (version 2) in monitoring hepatitis B virus-infected patients receiving nucleoside analog treatment.Recent advances in hepatitis B virus research: a German point of view.Novel lamivudine resistance.Hepatitis B virus drug resistance to current nucleos(t)ide analogs: Mechanisms and mutation sites.Exploring gene-deleted adenoviral vectors for delivery of short hairpin RNAs and reduction of hepatitis B virus infection in mice.
P2860
Q26852556-6DD205DB-CB0E-42E3-971E-6F9519100C5EQ27490400-65C2DE17-CC4B-410A-A0B9-7C3F6707B8ACQ28730089-C9608677-8CA8-460E-90A6-4ED123DC7CBBQ33370720-74BE3A07-FD61-41E8-8C29-822C69237241Q33393294-3C102C28-9145-4651-9FD0-2E998E1C9A0EQ33812160-28E05544-5A68-437F-BD8F-91FDC37F4808Q33940140-7FF8CD89-CC07-4621-BAB7-96C4630F8B4EQ34098571-AB81ED08-9380-4953-B481-3BF4EC7AF069Q34156859-C1622E7E-1907-4EBD-9E00-EAC47CAEE18DQ34233156-4AE579D6-CA06-47A8-A5D9-832ED5892C2BQ34335676-05E1F2DA-EB9F-43F4-931E-2FE12A4C9EEFQ34366437-27AF262E-3B7C-4FC2-B9C8-60E5F73559A6Q34485125-3229FAA7-DEB4-46F0-AA08-8ED928B37B2BQ34502260-F2E47C15-F978-495F-91FB-3E6AEB5620A0Q34756805-07E1EA76-97FF-4F4F-ADC9-2E3AA0A1795BQ35714962-F5E18E20-073D-4F3E-AE00-7EBD58491C86Q36151267-B41A37D5-E4C3-4BBF-9EC3-83A966102A02Q36736446-C3307D2C-49D8-40B5-8533-69538C8921CCQ36879784-66373B38-8049-4281-8AE1-0115620254A1Q37116860-D24E584A-6467-4BB7-90FE-4932C0DC9751Q37176668-6222A9B6-AA64-4940-81B0-29AC7DD93FEDQ37271725-ABE5EFD3-B1C4-40AE-8058-723BFE1C34C4Q37279114-D131CFBA-8AE4-450A-8D68-6DA630236F0EQ37285249-E41C2102-0A07-4A55-9B0B-974FF461A7D6Q37410736-76CA5D1D-DBF9-486E-9612-E8DEEB222B29Q37718052-171D1C7B-D1A2-45C0-A22D-EE3AFC6B7511Q38116098-91275B0C-1376-4E95-AC11-857AFA11E0F3Q38289404-A8722E9F-846D-4B63-86DD-6E1C31AEC4BFQ39217491-1444C6D7-337A-44DB-956F-D8B62CE69E22Q39746875-B8B47C5A-5AEE-4855-B328-BEC70B18EBC6Q40034536-290B306F-65B4-4985-83F0-9B49EA8344C2Q40154580-AC479243-4491-40BA-B26F-2BDD2C87DBA6Q41503381-DB97EBDD-F579-4783-AC3C-83DD9E53A1C0Q41610650-C672623D-F469-4D50-8494-70CC2001EDB8Q41718291-8594EBBC-6766-45C3-AB15-31C288AC89BFQ42124703-BED772CE-087D-431B-87F7-7BDD94327A28Q42703588-F1AA7B75-8C3E-4C77-8EC8-0C37D1B52D77Q42909077-F0F724E1-6735-4711-B6A5-76B259FC4409Q45363333-5CEB3F47-6F01-44B5-9E29-2E3580C5405EQ45395152-22CBD749-C6FA-4B7E-9941-4F7FDA3A6522
P2860
Antiviral therapy and resistance with hepatitis B virus infection.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Antiviral therapy and resistance with hepatitis B virus infection.
@ast
Antiviral therapy and resistance with hepatitis B virus infection.
@en
type
label
Antiviral therapy and resistance with hepatitis B virus infection.
@ast
Antiviral therapy and resistance with hepatitis B virus infection.
@en
prefLabel
Antiviral therapy and resistance with hepatitis B virus infection.
@ast
Antiviral therapy and resistance with hepatitis B virus infection.
@en
P2860
P356
P1476
Antiviral therapy and resistance with hepatitis B virus infection.
@en
P2093
Hans L Tillmann
P2860
P304
P356
10.3748/WJG.V13.I1.125
P407
P577
2007-01-01T00:00:00Z